BE1002255A5 - Medicaments. - Google Patents

Medicaments. Download PDF

Info

Publication number
BE1002255A5
BE1002255A5 BE8900221A BE8900221A BE1002255A5 BE 1002255 A5 BE1002255 A5 BE 1002255A5 BE 8900221 A BE8900221 A BE 8900221A BE 8900221 A BE8900221 A BE 8900221A BE 1002255 A5 BE1002255 A5 BE 1002255A5
Authority
BE
Belgium
Prior art keywords
methyl
acceptable salts
physiologically acceptable
drugs
carbazol
Prior art date
Application number
BE8900221A
Other languages
English (en)
Inventor
Michael Brian Tyers
Teresa Elizabeth Challoner
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10632894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1002255(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1002255A5 publication Critical patent/BE1002255A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne la co-administration en médecine humaine ou vétérinaire de 1,2,3,9-tétrahydro-9-méthyl-3-[(2-méthyl-1H-imidazol-1-yl)méthyl]-4H-carbazol-4-one ou d'un de ses sels ou produits de solvatation physiologiquement acceptables et de dexaméthasone ou d'un de ses sels ou esters physiologiquement acceptables. Les deux ingrédients actifs, qui peuvent être administrés séparément simultanément ou de façon séquentielle, ou peuvent être combinés en en une seule préparation pharmaceutique, sont utiles pour soulager et/ou prévenir la nausée et le vomissement.
BE8900221A 1988-03-04 1989-03-03 Medicaments. BE1002255A5 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888805269A GB8805269D0 (en) 1988-03-04 1988-03-04 Medicaments

Publications (1)

Publication Number Publication Date
BE1002255A5 true BE1002255A5 (fr) 1990-11-06

Family

ID=10632894

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8900221A BE1002255A5 (fr) 1988-03-04 1989-03-03 Medicaments.

Country Status (23)

Country Link
US (2) US6544550B1 (fr)
JP (1) JPH0296525A (fr)
KR (1) KR890014109A (fr)
AT (1) AT400301B (fr)
AU (1) AU626010B2 (fr)
BE (1) BE1002255A5 (fr)
CA (1) CA1319323C (fr)
CH (1) CH678149A5 (fr)
CY (1) CY1634A (fr)
CZ (1) CZ402391A3 (fr)
DE (1) DE3906883C2 (fr)
DK (1) DK175428B1 (fr)
FR (1) FR2627986B1 (fr)
GB (2) GB8805269D0 (fr)
HK (1) HK41792A (fr)
IE (1) IE61516B1 (fr)
IT (1) IT1232662B (fr)
NL (1) NL194463C (fr)
NZ (1) NZ228214A (fr)
SE (1) SE508342C2 (fr)
SG (1) SG9092G (fr)
SK (1) SK402391A3 (fr)
ZA (1) ZA891639B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929059A (en) * 1991-01-19 1999-07-27 Smithkline Beecham P.L.C. Pharmaceutical compositions containing granisetron and dexamethasone
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
ATE195867T1 (de) * 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
CN1118990A (zh) * 1993-03-08 1996-03-20 藤泽药品工业株式会社 治疗或预防脑血管疾病药物
US5661142A (en) * 1996-04-17 1997-08-26 Naeger; David M. Anti-emetic composition
US7288660B2 (en) * 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20050277624A1 (en) * 2004-06-09 2005-12-15 Nigel Cook Use of corticosteroids alone or in conjunction with nutritional therapy to reduce stress in animals
US20060263421A1 (en) * 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153821A (en) * 1984-01-25 1985-08-29 Glaxo Group Ltd 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives
EP0226266A2 (fr) * 1985-06-25 1987-06-24 Glaxo Group Limited Utilisation d'un dérivé du tétrahydrocarbazolone pour la fabrication de médicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0191562B1 (fr) * 1985-01-23 1991-07-10 Glaxo Group Limited Dérivés de tétrahydrocarbazolones
DE3688296T2 (de) * 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
GB8628475D0 (en) * 1986-11-28 1987-01-07 Glaxo Group Ltd Medicaments
PH25025A (en) * 1986-12-17 1991-01-28 Glaxo Group Ltd A method of treating dementia and other cognitive disorders using 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one
US4920219A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5246709A (en) * 1990-09-10 1993-09-21 Alza Corporation Antiemetic therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153821A (en) * 1984-01-25 1985-08-29 Glaxo Group Ltd 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives
EP0226266A2 (fr) * 1985-06-25 1987-06-24 Glaxo Group Limited Utilisation d'un dérivé du tétrahydrocarbazolone pour la fabrication de médicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 104, no. 21, 26 mai 1986, page 27, abrégé no. 179831n, Columbus, Ohio, US; M. HUO et al.: "Emesis induced by cisplatin and sulfatol 2-diaminocyclohexaneplatinum in dogs and its inhibition by antiemetics", & ZHONGGUO YAOLI XUEBAO 1986, 7(2), 182-4 *

Also Published As

Publication number Publication date
DK104389A (da) 1989-09-05
CY1634A (en) 1992-11-06
DE3906883C2 (de) 1998-11-05
GB2216414B (en) 1991-12-11
CA1319323C (fr) 1993-06-22
AU626010B2 (en) 1992-07-23
GB2216414A (en) 1989-10-11
DK104389D0 (da) 1989-03-03
ATA48389A (de) 1995-04-15
NL194463C (nl) 2002-05-03
CH678149A5 (fr) 1991-08-15
SK402391A3 (en) 2000-12-11
AU3097689A (en) 1989-09-07
ZA891639B (en) 1990-03-28
IE61516B1 (en) 1994-11-16
US5482716A (en) 1996-01-09
GB8805269D0 (en) 1988-04-07
JPH0296525A (ja) 1990-04-09
KR890014109A (ko) 1989-10-21
SE8900751D0 (sv) 1989-03-03
DE3906883A1 (de) 1989-09-14
SG9092G (en) 1992-03-20
AT400301B (de) 1995-12-27
NL194463B (nl) 2002-01-02
SE508342C2 (sv) 1998-09-28
HK41792A (en) 1992-06-19
CZ402391A3 (en) 1993-04-14
IT8947713A0 (it) 1989-03-03
NZ228214A (en) 1997-02-24
GB8904881D0 (en) 1989-04-12
SE8900751L (sv) 1989-09-05
US6544550B1 (en) 2003-04-08
FR2627986B1 (fr) 1994-03-04
NL8900526A (nl) 1989-10-02
FR2627986A1 (fr) 1989-09-08
IT1232662B (it) 1992-03-02
DK175428B1 (da) 2004-10-18
IE890697L (en) 1989-09-04

Similar Documents

Publication Publication Date Title
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
ATE315379T1 (de) Arzneimittel zur gesteuerten freisetzung von beta lactam antibiotika
MY118371A (en) Tetrahydrolipstatin containing compositions
FR2622798B1 (fr) Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires
MY100721A (en) Therapeutic agent.
BE1002249A4 (fr) Compositions pharmaceutiques.
NO863620L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
EP1027053A4 (fr) Procede pour prevenir la nephrotoxicite resultant de l'administration de cyclosporine et de tacrolimus
BE1002255A5 (fr) Medicaments.
BE1002295A5 (fr) Medicaments.
MY124465A (en) Reduction of infarct volume using citicoline
EP0302714A3 (fr) Composition pharmaceutique pour le traitement des maladies affaiblissant les os
BE1002256A3 (fr) Medicaments.
EP0190851B1 (fr) Composition anti-inflammatoire
US4355029A (en) Combination therapy for rheumatoid arthritis
RU95110494A (ru) Средство с регулируемым высвобождением пентоксифиллина для лечения сосудистых заболеваний
Bagheri et al. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
Rab et al. Double-blind multicentre isradipine dose-confirmation study in Pakistan
JPS6438027A (en) Remedy for cancer
CA2336711A1 (fr) Plaquette alveolaire contenant un systeme therapeutique transdermique et une forme galenique individuelle
Stewart " We have to go back to healing the traditional way," native speakers tell Manitoba MDs
EP0367509A3 (fr) Formulations

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *GLAXO GROUP LTD

Effective date: 20090303